March 22, 2018 / 12:59 PM / a year ago

AbbVie says not seeking accelerated approval for lung cancer drug

March 22 (Reuters) - Drugmaker AbbVie Inc said on Thursday it will not seek accelerated approval for its experimental lung cancer treatment based on results from a mid-stage study.

The study was testing the company’s Rova-T as a treatment for patients with small cell lung cancer who did not respond to at least two prior regimens.

Late-stage trials testing the drug as a treatment for patients in the earlier stages of the disease will continue, the company said. (Reporting by Tamara Mathias in Bengaluru; Editing by Anil D’Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below